Recent trials of early treatment with the nucleoside analogues have pr
oduced conflicting data, raising fundamental questions about this ther
apy. Nevertheless, these drugs do lengthen clinical latency and delay
the onset of AIDS, and for that reason alone should not be abandoned.
The new treatment guidelines of the National Institute of Allergy and
Infectious Diseases are discussed.